Pedro L Dago

  • 94 Citations
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

Mood disorders, Psychopharmacology

Certifications and Licenses


Training Experience

1991Internship, Saint Luke's Hospital
1994Residency, New York State Psychiatric Institute
1996Fellowship, New York State Psychiatric Institute

Education/Academic qualification

MD, University of Illinois - Chicago

… → 1990

Research interests

  • Anxiety Disorders
  • Cognitive Neuroscience
  • Depression
  • Mental Health
  • Mood Disorders
  • Neurology
  • Neuropsychology
  • Psychiatry

Fingerprint Dive into the research topics where Pedro L Dago is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 5 Similar Profiles
Bipolar Disorder Medicine & Life Sciences
Treatment-Resistant Depressive Disorder Medicine & Life Sciences
Piperazines Medicine & Life Sciences
Psychopharmacology Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Psychomotor Agitation Medicine & Life Sciences
Mood Disorders Medicine & Life Sciences
Antidepressive Agents Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2004 2012

Research Output 1995 2016

  • 94 Citations
  • 4 Article
  • 1 Comment/debate
  • 1 Letter
  • 1 Review article
21 Citations (Scopus)

Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia

Keefe, R. S. E., Haig, G. M., Marder, S. R., Harvey, P. D., Dunayevich, E., Medalia, A., Davidson, M., Lombardo, I., Bowie, C. R., Buchanan, R. W., Bugarski-Kirola, D., Carpenter, W. T., Csernansky, J. G., Dago, P. L., Durand, D. M., Frese, F. J., Goff, D. C., Gold, J. M., Hooker, C. I., Kopelowicz, A. & 5 others, Loebel, A., McGurk, S. R., Opler, L. A., Pinkham, A. E. & Stern, R. G., Jan 1 2016, In : Schizophrenia bulletin. 42, 1, p. 19-33 15 p.

Research output: Contribution to journalArticle

Clinical Trials
Reproducibility of Results

Introduction: Treatment along the life cycle

Dago, P., Sep 1 2013, In : Psychiatric Times. 30, 9

Research output: Contribution to journalComment/debate

Life Cycle Stages

Factors that impact choice of antidepressant treatment in medically complex patients.

Dago, P. L., Jan 1 2009, In : CNS Spectrums. 14, 12 Suppl 12, p. 20-27 8 p.

Research output: Contribution to journalArticle

Antidepressive Agents
Major Depressive Disorder
Serotonin and Noradrenaline Reuptake Inhibitors

An association of intrusive, repetitive phrase with lomotrigine treatment in bipolar II disorder

Kemp, D. E., Gilmer, W. S., Fleck, J. & Dago, P. L., Feb 1 2007, In : CNS Spectrums. 12, 2, p. 106-111 6 p.

Research output: Contribution to journalReview article

Bipolar Disorder
Vulnerable Populations
Mood Disorders
12 Citations (Scopus)

Aripiprazole augmentation for treatment-resistant bipolar depression: Sustained remission after 36 months [3]

Kemp, D. E., Dago, P. L., Straus, J. L., Fleck, J., Karaffa, M. & Gilmer, W. S., Jun 1 2007, In : Journal of Clinical Psychopharmacology. 27, 3, p. 304-305 2 p.

Research output: Contribution to journalLetter

Treatment-Resistant Depressive Disorder
Combination Drug Therapy
Bipolar Disorder